STAT Plus: Pfizer sues Trump administration over anti-kickback rules, saying they prevent it from helping lower seniors’ drug costs
WASHINGTON — Pharmaceutical giant Pfizer is suing the Trump administration over two long-standing Medicare rules that Pfizer says are blocking it from helping seniors pay for an expensive heart condition drug.
The lawsuit, which was filed in a federal court in New York Friday, concerns two planned copay assistance programs for Pfizer’s drug tafamidis, which treats a rare fatal heart disease, transthyretin amyloid cardiomyopathy. The company is hoping to overturn two long-standing federal policies: one that prevents drug makers from directly paying seniors’ drug bills, and another that keeps drug makers from coordinating directly with outside charities that offer similar programs.
